Table 2.
Sample characteristics: group 2 (Alzheimer’s disease, steady state amisulpride treatment)
| Variable | Mean ± SD Total sample (n = 25) |
Mean ± SD Men (n = 9) |
Mean ± SD Women (n = 16) |
|---|---|---|---|
| Age (years) | 81.8 ± 6.6 | 81.8 ± 7.7 | 81.8 ± 6.1 |
| MMSE (maximum 30) | 18.4 ± 5.4 | 19.8 ± 4.3 | 17.7 ± 5.8 |
| CrCL (ml/min) | 67.7 ± 17.3 | 67.8 ± 20.9 | 67.7 ± 17.4 |
| Weight (kg) | 68.0 ± 15.2 | 72.0 ± 8 | 65.8 ± 18 |
| BMI (kg/m2) | 26.5 ± 5.4 | 25.8 ± 1.8 | 26.9 ± 6.7 |
| Height (m) | 1.6 ± 0.1 | 1.7 ± 0.1* | 1.6 ± 0.1 |
| Creatinine (μmol/l) | 83.1 ± 25.7 | 97.4 ± 31.3* | 75.1 ± 18.5 |
| Daily dose at time of sampling (mg) | 49.4 ± 11.2 | 48.3 ± 6.4 | 48.1 ± 13.7 |
| Time since dose (h) | 16.2 ± 3.1 | 15.8 ± 3.2 | 16.3 ± 2.9 |
| Days treatment, current dose | 56.9 ± 58 | 62.6 ± 68.8 | 57.4 ± 56.8 |
| Amisulpride concentration (ng/ml) | 40.9 ± 27.1 | 41.5 ± 26.2 | 40.5 ± 28.1 |
| Dose-corrected concentration (ng/ml/mg) | 0.85 ± 0.53 | 0.87 ± 0.52 | 0.84 ± 0.54 |
Values for men and women were compared using independent samples t tests
MMSE Mini Mental State Examination, CrCL estimated creatinine clearance (ml/min—converted to l/h for the purposes of model building, BMI body mass index (kg/m2), Cmax peak plasma concentration (ng/ml—converted to l/h for the purposes of model building
*p < 0.05